GLP1R and type 2 diabetes mellitus: Based on the evidence provided by these trials and meta-analysis, the ESC, ADA, and EASD guidelines recommend initiation of GLP-1 receptor agonists with proven benefits, irrespective of diabetes control, in patients with cardiovascular disease and T2DM (10, 59).